寰泰生技 2025年季度报告

ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________. Commission File No.000-24657MANNATECH, INCORPORATED(Exact Name of Registrant as Specified in its Charter) Registrant’s Telephone Number, including Area Code:(972)471-7400Securities registered pursuant to Section 12(b) of the Act: Trading Symbol(s) Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).YesxNoo YesoNoxAs of May6, 2025, the number of shares outstanding of the registrant’s sole class of common stock, par value $0.0001 per share, was Part I – FINANCIAL INFORMATIONItem 1. Financial StatementsCondensed Consolidated Balance Sheets (unaudited)Condensed Consolidated Statements of Operations (unaudited)Condensed Consolidated Statements of Comprehensive Loss (unaudited) Notes to Condensed Consolidated Financial Statements (unaudited) Results of OperationsLiquidity and Capital Resources Part II – OTHER INFORMATIONItem 1. Legal Proceedings Item 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety Disclosures Item 6. Exhibits the impact of future market changes due to exposure to foreign currency translations;the possibility of certain policies, procedures, and internal processes minimizing exposure to market risk; the outcome of new or existing litigation matters;the outcome of new or existing regulatory inquiries or investigations; andother assumptions described in this report underlying such forward-looking statements. statements are subject to certain events, risks, assumptions, and uncertainties, including those discussed below, the “Risk Factors” section inPart I, Item 1A of our Form 10-K for the year ended December31, 2024, and elsewhere in this Form 10-Q and the documents incorporated byreference herein. If one or more of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual resultsand developments could materially differ from those expressed in or implied by such forward-looking statements. For example, any of thefollowing factors could cause actual results to vary materially from our projections: overall growth or lack of growth in the nutritional supplements industry;plans for expected future product development;changes in manufacturing costs;shifts in the mix of packs and products;the future impact of any changes to global associate career and compensation plans or incentives or the regulations governingsuch plans and incentives;the ability to attract and retain independent associates and preferred customers;new regulatory changes that may affect operations, products or compensation plans and incentives;ability of our outside suppliers and manufacturers to supply products in sufficient quantities and comply withour product safety and quality standards or applicable law;the competitive nature of our business with respect to products and pricing; the political, social and economic climate of the countries in which we operate.Forward-looking statements generally can be identified by use of phrases or terminology such as “may,” “will,” “should,” “could,”“would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “approximates,” “predicts,” “projects,” “hopes,” “potential,” and“continues” or other similar words or the negative of such terms and other comparable terminology. Similarly, descriptions of Mannatech’s Unless stated otherwise, all financial information throughout this report and in the Condensed Consolidated Financial Statements andrelated Notes include Mannatech, Incorporated and all of its subsidiaries on a consolidated basis and may be referred to herein as “Mannatech,”“the Company,” “its,” “we,” “us,” “our,” or “their.”Our products are not intended to diagnose, cure, treat, or prevent any disease, and any statements about our products contained in thisreport have not been evaluated by the Food and Drug Administration, also referred to herein as the “FDA”. CONDENSED CONSOLIDATED BALANCE SHEETS –(UNAUDITED)(in thousands, except share and per share amounts) Accounts receivable, net of allowance of $876 and $935Income tax receivable Total current assets26,545Property and equipment, net3,089Operang lease right-of-use assets1,963Other assets2,676Deferred tax assets, net1,826Long-term restricted cash570 Accrued expenses4,307Deferred revenue2,322Accounts payable4,373Current poron of operang lease liabilies981 Current notes payable—Current poron offinance lease liabilies279 Finance lease liabilies, excluding current poron Commitments and conngencies Addional paid-in capital(Accumulated deficit) retained earningsAccumulated other comprehensive lossTreasury stock, at averagecost, 841,927 shares as of March 31, 2025 and 858,043 shares asof December 31, 2024Total share